Nasdaq:US$32.17 (+0.00) | HKEX:HK$50.40 (+0.75) | AIM:£4.71 (+0.02)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial

Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong

Venue: Chinese Society of Clinical Oncology Annual Meeting
Session: Esophageal Cancer
Presenter: Jifang Gong
Date: Thursday, September 28, 2017